English deutsch Impressum
Sitemap Disclaimer
Company Product Investor Relations Newsroom Careers Contact
 

Share
News
 Press Releases
 Ad hoc announcement
Financial reports
Presentations
general Meeting
Corporate Governance
Dates & Events
Annual Document
IR Service

Ad hoc Announcements

06 June 2008 WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE®* (CA9-SCAN)
13 Dec 2007 WILEX announces positive result of the interim analysis for futility of its Phase III ARISER trial with RENCAREX®*
12 Oct 2007 WILEX´ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCAN
01 Oct 2007 Supervisory Board appoints Dr. Thomas Borcholte as Chief Business Officer and member of Executive Management Board of WILEX AG
12 July 2007 WILEX AG - improved financial outlook due to cost optimization
15 Dec 2006 WILEX receives approval for clinical Phase II trial with oral WX-671 in pancreatic cancer
10 Nov 2006 WILEX shares successfully placed at EUR 13.80
06 Nov 2006 Price range for WILEX shares set at EUR 13.80 to EUR 15.80

* temporary name while under development

© 2006 WILEX AG